Evidence map›Paper›PMID 42115980›Full record

ArticleBMC infectious diseases2026

Hospitalization and diabetes mellitus as predictors of unfavorable tuberculosis treatment outcomes.

Edson Beyker de Mendonça, Mariana Araújo-Pereira, Rodrigo Carvalho de Menezes, Caian Leal de Azevedo Vinhaes, Carolina Arana Stanis Schmaltz, Flavia Marinho Sant'Anna, Felipe Moreira Ridolfi, Bruno de Bezerril Andrade, Valeria Cavalcanti Rolla

Abstract read
In one paragraph

Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Edson Beyker de Mendonça *Postgraduate Program "Clinical Research in Infectious Diseases", National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. edson.beyker@ini.fiocruz.br.
Mariana Araújo-Pereira *Institute of Clinical and Translational Research, Medicina Zarns, Salvador, Brazil.
Rodrigo Carvalho de MenezesInstitute of Clinical and Translational Research, Medicina Zarns, Salvador, Brazil.
Caian Leal de Azevedo VinhaesInstitute of Clinical and Translational Research, Medicina Zarns, Salvador, Brazil.
Carolina Arana Stanis SchmaltzClinical Research Laboratory on Mycobacteria (LAPCLIN-TB), National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Flavia Marinho Sant'AnnaClinical Research Laboratory on Mycobacteria (LAPCLIN-TB), National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Felipe Moreira RidolfiClinical Research Laboratory on Mycobacteria (LAPCLIN-TB), National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Bruno de Bezerril Andrade *Institute of Clinical and Translational Research, Medicina Zarns, Salvador, Brazil.
Valeria Cavalcanti Rolla *Postgraduate Program "Clinical Research in Infectious Diseases", National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. valeria.rolla@ini.fiocruz.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTuberculosis (TB) remains a global challenge, with 10.8 million cases and 1.25 million deaths annually. This study aimed to identify baseline characteristics of TB participants associated with treatment failure and death.

methodsThis retrospective cohort study enrolled adult participants with TB treated between 2015 and 2022 at a Brazilian referral center. Comprehensive baseline data (socioeconomics, demographics, clinicals, and laboratory tests) and monthly follow-up visits data were extracted from electronic medical records. Outcomes followed WHO 2021 criteria. Backward stepwise multivariable regression analysis was performed to identify predictors independently associated with failure and death.

resultsAmong 485 participants (61.2% male, median age 38.0 years), 7.2% (N = 35) had unfavorable outcomes, comprising 1.8% death (N = 9) and 5.4% treatment failure (N = 26), the latter primarily driven by regimen changes due to adverse drug reactions (22/26 cases) rather than microbiological failure. Univariate analysis identified a higher proportion of unfavorable outcomes among people living with HIV (57.1% vs. 32.9%; p = 0.007), as well as in baseline hospitalization (48.6% vs. 14.0%; p < 0.001), disseminated TB (25.7% vs. 8.9%; p = 0.014), and alcohol (60.0% vs. 29.3%; p = 0.001) or tobacco consumption (48.6% vs. 21.8%; p = 0.002). Participants with unfavorable outcomes had lower hemoglobin (10.8 vs. 12.1 g/dL; p = 0.018), albumin (2.7 vs. 3.3 g/dL; p < 0.001), and lymphocyte count (1,111 vs. 1,561/µL; p = 0.003), as well as elevated C-reactive protein (9.54 vs. 4.93 mg/dL; p = 0.013), aspartate aminotransferase (37.0 vs. 24.0 U/L; p < 0.001) and gamma-glutamyl transferase (117.0 vs. 64.4 U/L; p = 0.001). Multivariate analysis identified baseline hospitalization (adjusted Odds Ratio [aOR] = 3.21, 95% confidence interval [CI] 1.42-7.26) and diabetes mellitus (DM) (aOR = 3.04, 95%CI 1.10-8.45) as independent predictors of unfavorable outcomes, whereas associations with alcohol use, and previous TB treatment were attenuated after adjustment, indicating possible confounding.

conclusionDM and baseline hospitalization independently predict unfavorable TB outcomes, highlighting their importance for early risk stratification, while other factors, such as laboratory abnormalities, may primarily reflect secondary effects of disease severity captured by hospitalization. CLINICAL TRIAL: Not applicable.

Indexed as

Antitubercular AgentsDiabetes MellitusHospitalizationTuberculosisAdultBrazilFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsTreatment FailureTreatment OutcomeAntitubercular AgentsDiabetes mellitusHospitalizationTreatment outcomesTuberculosis

Identifiers

PMID42115980
PMCPMC13335336

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.